Need for Vitamin D in DLBCL

The effect of vitamin D deficiency (VDD) in elderly patients with diffuse large B-cell lymphoma (DLBCL) was examined. 

Patients (n = 359) with pretreatment 25-hydroxyvitamin D3 (25[OH]D3) serum levels from the RICOVER-60 study and 63 patients from the RICOVER-noRTh study were investigated.

Patients form the RICOVER-60 study could receive rituximab; in the RICOVER-noRTh study, patients received two cycles of rituximab but no radiotherapy. Lactate dehydrogenase release assay of CD20+ Daudi cells was used to assess rituximab-mediated cytotoxicity (RMCC). Patients from the RICOVER-60 study with VDD (=8 ng/mL) and vitamin D levels =8 ng/mL treated with rituximab had a three-year event-free survival (EFS) of 59% and 79% and three-year overall survival (OS) of 70% and 82%, respectively. In multivariate analysis adjusting for International Prognostic Index risk factors these differences were significant with a hazard ratio of 2.1 (p = 0.008) for EFS and 1.9 (p = 0.040) for OS. In those not treated with rituximab, EFS was not significantly different in patients with vitamin D levels =8 ng/mL or =8 ng/mL. Following substitution and normalisation of vitamin D levels, RMCC increased significantly (p<0.001) in the seven patients with VDD. For more information, click here.


Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe


Have you ever attended a meeting with a lymphoma support group?




The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 03/27/18. Copyright © 2018 Lymphoma Coalition. All rights reserved.